LLY
Eli Lilly and Company
LLY has the edge over REGN overall, supported by stronger valuation and stronger fundamentals.
REGN
Regeneron Pharmaceuticals, Inc.
REGN has slightly lower modeled downside risk, despite its lower overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
REGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Healthy | |
| Strong |
REGN's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
REGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $951 | — |
| Cheap | 13x | $589 | -38% |
| Fair | 18x | $822 | -14% |
| Current | 21x | $951 | — |
| Expensive | 25x | $1,135 | +19% |
Historical ranges are pointers, not guarantees.
REGN has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
REGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for REGN, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over REGN on earnings, with stronger typical year-over-year growth.
REGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $79.95 | +77% |
| Q3 2026 | $45.21 | +8.1% |
| Q2 2026 | $40.38 | +1.6% |
| Q1 2026 | $40.96 | +4.1% |
| Q4 2025 | $41.48 | +8.2% |
| Q3 2025 | $41.82 | +3.4% |
| Q2 2025 | $39.74 | +5.2% |
| Q1 2025 | $39.34 | +16% |
| Q4 2024 | $38.34 | +10% |
REGN's earnings per share have fallen from their peak: $45.21 over the past year, against $71.97 in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over REGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
REGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +36% |
| Q2 2026 | $4.3B | +17% |
| Q1 2026 | $3.6B | +19% |
| Q4 2025 | $3.9B | +2.5% |
| Q3 2025 | $3.8B | +0.9% |
| Q2 2025 | $3.7B | +3.6% |
| Q1 2025 | $3B | -3.7% |
| Q4 2024 | $3.8B | +10% |
REGN's revenue has grown year over year for six quarters in a row: $5.1B last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | +13 points |
| Q2 2026 | 30% | +0.8 points |
| Q1 2026 | 18% | -1.7 points |
| Q4 2025 | 23% | -3.5 points |
| Q3 2025 | 27% | -4.3 points |
| Q2 2025 | 29% | -0.8 points |
| Q1 2025 | 20% | -4.4 points |
| Q4 2024 | 26% | -2.2 points |
REGN has the edge over LLY on profitability, with a higher operating margin.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over REGN on cash flow, with more consistent year-over-year improvement.
REGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.6% |
| Q2 2026 | $572.8M | -38% |
| Q1 2026 | $848.3M | +4% |
| Q4 2025 | $922M | -13% |
| Q3 2025 | $1.4B | +35% |
| Q2 2025 | $925.4M | +433% |
| Q1 2025 | $815.8M | -41% |
| Q4 2024 | $1.1B | +27% |
REGN still generates free cash flow, though less than at its 2021 peak: $3.8B over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
REGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -400K shares |
| 1 year | -1.5% | -1.6M shares |
| 3 years | -6.9% | -7.8M shares |
| 5 years | -7.3% | -8.3M shares |
| Available history | -7.9% | -9M shares |
REGN has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $399.7M |
| Q2 2026 | $1.2B |
| Q1 2026 | $794.3M |
| Q4 2025 | $671.7M |
| Q3 2025 | $664M |
| Q2 2025 | $1.1B |
| Q1 2025 | $1B |
| Q4 2024 | $973M |
REGN spent $3B buying back its own shares over the past year, down 19% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
REGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Very low |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
REGN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
REGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.3 | Neutral |
| Stochastic | 83.3 | Overbought |
REGN's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
REGN PE vs Healthcare Sector
| Metric | REGN | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 19% below |
| PE % | 70 | 29 | 41 pts above |
REGN has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
REGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $831.1 | 14% above |
| 20 week MA | $783.7 | 21% above |
| 50 week MA | $749.7 | 27% above |
| 100 week MA | $681.9 | 39% above |
| 200 week MA | $782.7 | 22% above |
REGN has climbed back above all five of its weekly moving averages, and it's now 22% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over REGN on returns for 2026, with the stronger performance.
REGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $373.3 | $488.9 | +31% |
| 2021 | $488.9 | $625.4 | +28% |
| 2022 | $625.4 | $726.7 | +16% |
| 2023 | $726.7 | $878.3 | +21% |
| 2024 | $878.3 | $712.4 | -19% |
| 2025 | $712.4 | $785.0 | +10% |
| 2026 YTD | $785.0 | $951.2 | +21% |
REGN has finished higher in five of the last six years. It's up 21% so far in 2026.